Medication comprising nicotinic acid and tatin-like medicine

A drug and statin technology, applied in the field of drugs containing niacin and statins, can solve the problems of limited clinical application, serious liver side effects, and many adverse reactions of niacin.

Inactive Publication Date: 2004-03-31
AFFILIATED HOSPITAL CHINA ACADEMY OF MILITARY MEDICAL SCI
View PDF0 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are many adverse reactions of niacin, which limits its clinical application.
[0004] The use of large doses of niacin often causes side effects such as flushing and liver toxicity. For this reason, in the 1980s, the United States launched sustained-release capsules with a specif

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Sustained-release niacin layer prescription (dosage per tablet)

[0014] Niacin 500mg

[0015] Hypromellose (HPMC K4M ) 203mg

[0016] povidone k 30 17mg

[0017] Stearic acid 7.3mg

[0018] 70% ethanol appropriate amount

[0019] Prescription of lovastatin layer (dosage per tablet)

[0020] Lovastatin 20mg

[0021] Lactose 100mg

[0022] Starch 180mg

[0023] Stearic acid 3mg

[0024] 70% ethanol appropriate amount

[0025] Take niacin and statin and pass through a 100-mesh sieve respectively, and starch, lactose, HPMC, PVP and stearic acid pass through a 100-mesh sieve for later use. Prepare 1000 samples: Mix niacin (500g) with HPMC (203g) and PVP (17g) and pass through a 60-mesh sieve to mix evenly; add 70% ethanol, mix to prepare a soft material, pass through a 16-mesh sieve to granulate; granulate at 60°C Dry for 2 hours, take out and add stearic acid (7.3g) to mix, pass through a 18-mesh sieve and granulate to obtain niacin l...

Embodiment 2

[0027] Sustained-release niacin layer prescription (dosage per tablet)

[0028] Niacin 750mg

[0029] Hypromellose (HPMC K4M ) 210mg

[0030] povidone k 30 17.2mg

[0031] Stearic acid 7.3mg

[0032] 70% ethanol appropriate amount

[0033] Prescription of lovastatin layer (dosage per tablet)

[0034] Lovastatin 20mg

[0035] Lactose 100mg

[0036] Starch 180mg

[0037] Stearic acid 3mg

[0038] 70% ethanol appropriate amount

Embodiment 3

[0040] Sustained-release niacin layer prescription (dosage per tablet)

[0041] Niacin 1000mg

[0042] Hypromellose (HPMC K4M ) 227mg

[0043] povidone k 30 17.2mg

[0044] Stearic acid 7.3mg

[0045] 70% ethanol appropriate amount

[0046] Prescription of lovastatin layer (dosage per tablet)

[0047] Lovastatin 20mg

[0048] Lactose 100mg

[0049] Starch 180mg

[0050]Stearic acid 3mg

[0051] 70% ethanol appropriate amount

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to medicament containing nicacid or other Statin drugs, which is a double layer tablet, one of which contains clinically effective dose nicacid and slow release preparation findings acceptable in pharmaceutics, while the other layer contains clinically effective dose Statin drugs and slow release preparation findings acceptable in pharmaceutics.

Description

technical field [0001] The invention relates to a pharmaceutical composition containing niacin and statins. The pharmaceutical composition is a double-layer tablet, and the niacin and statins are not mixed together. Background technique [0002] The relationship between dyslipidemia and atherosclerosis (AS), especially coronary heart disease (CHD), has been studied for nearly a century. In recent years, research in this area has been very active. More and more research results have shown that dyslipidemia is the pathogenesis of CHD. one of the risk factors. Therefore, it is necessary to take necessary measures to reduce the incidence of related diseases in order to reduce the incidence of related diseases. [0003] Nicotinic acid, also known as nicotine acid, belongs to the B vitamins and is used to treat abnormal lipoprotein metabolism. Niacin is the only compound known so far that can make all the basic components of blood lipids develop in the right direction. Its great...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/455A61P3/06
Inventor 付桂英温明铃邹鹏贾立华杨郡潘强龚文琴王世岭
Owner AFFILIATED HOSPITAL CHINA ACADEMY OF MILITARY MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap